Short answer
Incyte (INCY) filed its Q2 2026 10-Q quarterly report on Jul 28, 2026 for the quarter ended Jun 30, 2026.
Incyte Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Near-term outlook: Phase 3 INCA033989 MF trial anticipated in second half of 2026
- Emerging headwinds: reimbursement, drug pricing, competition, regulatory, and geopolitical risks flagged
Risk Factors
- New risk trigger: JAKAFI patent exclusivity expiration in 2028, with expected product-sales decline thereafter
- Commercial risk: Dependence on JAKAFI, expected to contribute a significant percentage of revenues over the next several years
- Regulatory risk: FDA boxed warnings for OPZELURA and JAKAFI-class risks could reduce future product sales
- Market risk: Competitors may commercialize safer, more effective, convenient, or less expensive alternatives
- Distribution risk: Limited specialty pharmacies and wholesalers handle significant JAKAFI and other-product revenues
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Incyte quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.